Orexo AB (publ) (ORX.ST)
SEK 20.8
(-5.24%)
SEK 20.8
(-5.24%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 786.6 Million SEK | -29.07% |
| 2022 | 1.1 Billion SEK | -12.93% |
| 2021 | 1.27 Billion SEK | 3.31% |
| 2020 | 1.23 Billion SEK | -17.87% |
| 2019 | 1.5 Billion SEK | 16.66% |
| 2018 | 1.28 Billion SEK | 28.17% |
| 2017 | 1 Billion SEK | -1.46% |
| 2016 | 1.01 Billion SEK | 0.25% |
| 2015 | 1.01 Billion SEK | -17.1% |
| 2014 | 1.22 Billion SEK | 58.73% |
| 2013 | 772.33 Million SEK | 60.32% |
| 2012 | 481.75 Million SEK | -11.78% |
| 2011 | 546.1 Million SEK | -23.37% |
| 2010 | 712.69 Million SEK | 9.76% |
| 2009 | 649.33 Million SEK | -7.51% |
| 2008 | 702.02 Million SEK | -12.45% |
| 2007 | 801.87 Million SEK | 111.06% |
| 2006 | 379.93 Million SEK | 2.32% |
| 2005 | 371.31 Million SEK | 250.24% |
| 2004 | 106.01 Million SEK | 134.8% |
| 2003 | 45.15 Million SEK | 35.8% |
| 2002 | 33.24 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 829.9 Million SEK | 5.5% |
| 2024 Q2 | 773.3 Million SEK | -6.82% |
| 2024 Q3 | 697 Million SEK | -9.87% |
| 2023 FY | 786.6 Million SEK | -29.07% |
| 2023 Q1 | 949.3 Million SEK | -14.4% |
| 2023 Q3 | 869 Million SEK | -6.25% |
| 2023 Q4 | 786.6 Million SEK | -9.48% |
| 2023 Q2 | 926.9 Million SEK | -2.36% |
| 2022 Q1 | 1.2 Billion SEK | -5.34% |
| 2022 FY | 1.1 Billion SEK | -12.93% |
| 2022 Q4 | 1.1 Billion SEK | -7.85% |
| 2022 Q2 | 1.27 Billion SEK | 5.42% |
| 2022 Q3 | 1.2 Billion SEK | -5.31% |
| 2021 Q2 | 1.34 Billion SEK | -6.18% |
| 2021 Q1 | 1.43 Billion SEK | 16.27% |
| 2021 FY | 1.27 Billion SEK | 3.31% |
| 2021 Q4 | 1.27 Billion SEK | -2.93% |
| 2021 Q3 | 1.31 Billion SEK | -2.44% |
| 2020 Q3 | 1.32 Billion SEK | -9.21% |
| 2020 Q4 | 1.23 Billion SEK | -7.18% |
| 2020 Q1 | 1.55 Billion SEK | 3.28% |
| 2020 Q2 | 1.46 Billion SEK | -5.64% |
| 2020 FY | 1.23 Billion SEK | -17.87% |
| 2019 Q1 | 1.36 Billion SEK | 6.27% |
| 2019 FY | 1.5 Billion SEK | 16.66% |
| 2019 Q4 | 1.5 Billion SEK | -2.86% |
| 2019 Q3 | 1.54 Billion SEK | 7.31% |
| 2019 Q2 | 1.44 Billion SEK | 5.32% |
| 2018 Q3 | 1.2 Billion SEK | 2.97% |
| 2018 Q1 | 1.03 Billion SEK | 3.14% |
| 2018 Q2 | 1.17 Billion SEK | 13.34% |
| 2018 FY | 1.28 Billion SEK | 28.17% |
| 2018 Q4 | 1.28 Billion SEK | 6.49% |
| 2017 Q4 | 1 Billion SEK | -2.85% |
| 2017 Q3 | 1.03 Billion SEK | 5.85% |
| 2017 Q2 | 976.2 Million SEK | 4.28% |
| 2017 FY | 1 Billion SEK | -1.46% |
| 2017 Q1 | 936.1 Million SEK | -8.12% |
| 2016 FY | 1.01 Billion SEK | 0.25% |
| 2016 Q4 | 1.01 Billion SEK | -5.02% |
| 2016 Q3 | 1.07 Billion SEK | -1.19% |
| 2016 Q2 | 1.08 Billion SEK | 6.09% |
| 2016 Q1 | 1.02 Billion SEK | 0.68% |
| 2015 Q4 | 1.01 Billion SEK | -8.44% |
| 2015 Q2 | 1.18 Billion SEK | -4.65% |
| 2015 Q1 | 1.24 Billion SEK | 1.18% |
| 2015 FY | 1.01 Billion SEK | -17.1% |
| 2015 Q3 | 1.11 Billion SEK | -6.15% |
| 2014 Q2 | 915.1 Million SEK | 22.98% |
| 2014 Q1 | 744.1 Million SEK | -3.66% |
| 2014 Q3 | 1.17 Billion SEK | 28.03% |
| 2014 Q4 | 1.22 Billion SEK | 4.63% |
| 2014 FY | 1.22 Billion SEK | 58.73% |
| 2013 Q2 | 591.7 Million SEK | 17.68% |
| 2013 FY | 772.33 Million SEK | 60.32% |
| 2013 Q4 | 772.33 Million SEK | 20.08% |
| 2013 Q3 | 643.2 Million SEK | 8.7% |
| 2013 Q1 | 502.8 Million SEK | 4.37% |
| 2012 Q4 | 481.75 Million SEK | -14.66% |
| 2012 Q3 | 564.5 Million SEK | -17.99% |
| 2012 FY | 481.75 Million SEK | -11.78% |
| 2012 Q1 | 488.4 Million SEK | -10.57% |
| 2012 Q2 | 688.3 Million SEK | 40.93% |
| 2011 FY | 546.1 Million SEK | -23.37% |
| 2011 Q4 | 546.1 Million SEK | -32.86% |
| 2011 Q3 | 813.36 Million SEK | -6.52% |
| 2011 Q2 | 870.09 Million SEK | 31.01% |
| 2011 Q1 | 664.14 Million SEK | -6.81% |
| 2010 Q3 | 708.24 Million SEK | -7.48% |
| 2010 Q4 | 712.69 Million SEK | 0.63% |
| 2010 FY | 712.69 Million SEK | 9.76% |
| 2010 Q1 | 597.86 Million SEK | -7.93% |
| 2010 Q2 | 765.5 Million SEK | 28.04% |
| 2009 FY | 649.33 Million SEK | -7.51% |
| 2009 Q3 | 683.15 Million SEK | 0.0% |
| 2009 Q4 | 649.33 Million SEK | -4.95% |
| 2008 Q4 | 702.02 Million SEK | 0.0% |
| 2008 FY | 702.02 Million SEK | -12.45% |
| 2007 FY | 801.87 Million SEK | 111.06% |
| 2006 FY | 379.93 Million SEK | 2.32% |
| 2005 FY | 371.31 Million SEK | 250.24% |
| 2004 FY | 106.01 Million SEK | 134.8% |
| 2003 FY | 45.15 Million SEK | 35.8% |
| 2002 FY | 33.24 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AcuCort AB | 58.5 Million SEK | -1244.455% |
| AlzeCure Pharma AB (publ) | 32 Million SEK | -2358.048% |
| BioGaia AB (publ) | 2.33 Billion SEK | 66.286% |
| Enzymatica AB (publ) | 125.91 Million SEK | -524.727% |
| Enorama Pharma AB (publ) | 34.38 Million SEK | -2187.625% |
| Gabather AB (publ) | 2.93 Million SEK | -26682.431% |
| Klaria Pharma Holding AB (publ.) | 73.12 Million SEK | -975.766% |
| Moberg Pharma AB (publ) | 634.73 Million SEK | -23.926% |
| Nanexa AB (publ) | 132.25 Million SEK | -494.751% |
| Newbury Pharmaceuticals AB (publ) | 90.87 Million SEK | -765.623% |
| ODI Pharma AB | 12.27 Million SEK | -6308.15% |
| Probi AB (publ) | 1.55 Billion SEK | 49.265% |
| Swedencare AB (publ) | 9.52 Billion SEK | 91.739% |
| Swedish Orphan Biovitrum AB (publ) | 74.02 Billion SEK | 98.937% |
| Toleranzia AB | 160.42 Million SEK | -390.316% |
| Vivesto AB | 355.87 Million SEK | -121.032% |